CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 103 enrolled
Drug / intervention
Dupilumab +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03558997
NCT03558997Phase 2Completed

A Study To Evaluate The Efficacy Of Dupilumab As An Adjunct For Subcutaneous Grass Immunotherapy To Reduce Provoked Allergic Rhinitis Symptoms Using The Nasal Allergen Challenge Model

Regeneron Pharmaceuticals·interventional·Posted Jun 15, 2018·Updated May 28, 2020

In Brief

A Phase 2 clinical trial evaluating Dupilumab, Timothy Grass SCIT, and 2 other interventions for Allergic Rhinitis. Completed, enrolled 103 participants across 17 sites in 2 countries.

Detailed Summary

The primary objective is to assess whether 16 weeks of treatment with dupilumab as an adjunct to Timothy Grass Subcutaneous Immunotherapy (SCIT) improves upon the efficacy of Timothy Grass SCIT to reduce provoked allergic rhinitis symptoms, as measured by Total Nasal Symptom Score (TNSS) after nasal allergen challenge (NAC) with Timothy Grass extract at week 17. The secondary objectives of the study are: * To assess whether 16 weeks of treatment with dupilumab as compared to placebo reduces provoked allergic rhinitis symptoms, as measured by TNSS after nasal allergen challenge (NAC) with Timothy Grass extract * To assess whether 16 weeks of treatment with dupilumab as compared to dupilumab + SCIT reduces provoked allergic rhinitis symptoms, as measured by TNSS after nasal allergen challenge (NAC) with Timothy Grass extract * To assess changes in serum Timothy-grass-specific immunoglobulin G4 (IgG4), serum Timothy grass-specific immunoglobulin E (IgE), and ratio of serum Timothy Grass-specific IgG4 to IgE over 16 weeks of treatment with dupilumab + SCIT as compared to SCIT monotherapy * To evaluate the safety and tolerability of 16 weeks of treatment with dupilumab as an adjunct to Timothy Grass SCIT

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesCanada, United States
CollaboratorsSanofi

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedJun 15, 2018
Enrollment StartJun 7, 2018
Primary CompletionMay 14, 2019
Study CompletionJun 13, 2019
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 8.0 years ago

Interventions

Dupilumabdrug

Dupilumab was administered SC in a single-use, pre-filled glass syringe

Timothy Grass SCITdrug

Timothy grass extract was administered SC.

Placebo matching dupilumabdrug

Placebo matching dupilumab was prepared in the same formulation without the addition of protein

Placebo matching SCITdrug

Placebo matching SCIT was prepared in the same formulation (SCIT diluent) without the addition of Timothy grass extract